Tris Pharma has initiated an expansion of its manufacturing capacity earlier in 2012 and is roughly midway through a 15 month expansion.
The expansion will take the company’s footprint from its current 90,000ft² to approximately 200,000 ft². The first phase will double the cGMP capacity.
Tris has received five new ANDA approvals from the FDA, beginning with the generic version of Delsym.
Tris president and CEO Ketan Mehta said that expanding manufacturing capacity is a critical part of the growth equation but equally important is having the right team to manage the dynamic and complex supply chain.
“To that end, we have added several new managerial positions and were very fortunate to have recruited David Palew, a seasoned supply chain executive, for the newly created position of Senior Director of Supply Chain,” Mehta added.
The company has appointed Dave Palew to lead the supply chain team, co-lead ERP implementation team and work with all its suppliers and external marketing partners.
